

**CHANGE - ANNOUNCEMENT OF APPOINTMENT::RE-DESIGNATION OF CHIEF COMMERCIAL OFFICER TO CHIEF OPERATING OFFICER**

## Issuer &amp; Securities

## Issuer/Manager

CLEARBRIDGE HEALTH LIMITED

## Securities

CLEARBRIDGE HEALTH LIMITED - SG1EB6000000 - 1H3

## Stapled Security

No

## Announcement Details

## Announcement Title

Change - Announcement of Appointment

## Date &amp; Time of Broadcast

06-Jan-2021 18:07:06

## Status

New

## Announcement Sub Title

Re-designation of Chief Commercial Officer to Chief Operating Officer

## Announcement Reference

SG210106OTHR7F2U

## Submitted By (Co./Ind. Name)

Chen Johnson

## Designation

Non-Executive Non-Independent Chairman

## Description (Please provide a detailed description of the event in the box below)

Re-designation of Chief Commercial Officer to Chief Operating Officer.

## Additional Details

## Date Of Appointment

06/01/2021

## Name Of Person

Liau Yen San, Jonathan

## Age

42

**Country Of Principal Residence**

Singapore

**The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)**

The board of directors of the Company, having reviewed and considered Mr Liao's qualifications and experience, concurred with the recommendation of the nominating committee of the Company and approved the re-designation of Mr Liao as Chief Operating Officer.

**Whether appointment is executive, and if so, the area of responsibility**

Executive.

Responsible for overseeing commercial strategy, new products/services initiatives and general development and management responsibilities of the Group with a view to strategise, streamline and improve operating performance.

**Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)**

Chief Operating Officer

**Professional qualifications**

- 1) Master of Biochemical Engineering (Bioprocess Management), University College London, UK
- 2) Master of Business Administration, University of Chicago, US

**Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or any of its principal subsidiaries**

Not Applicable

**Conflict of interests (including any competing business)**

Not Applicable

**Working experience and occupation(s) during the past 10 years**

August 2017 - Present

Clearbridge Health Limited - Chief Commercial Officer

June 2016 - August 2017

EDBI Pte Ltd - Vice President, Investment

July 2013 - June 2016

Cordlife Group Limited ("Cordlife") - Senior Director, Corporate Development

November 2004 - June 2013

Cordlife Services (S) Pte Ltd (now known as Life Corporation Services (S) Pte Ltd) - Chief Operating Officer

**Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))**

Yes

**Shareholding interest in the listed issuer and its subsidiaries?**

Yes

### Shareholding Details

Mr Liao holds 5,019,760 ordinary shares (approximately 0.82%) in the Company. In addition, Mr Liao subscribed S\$200,000 convertible bonds issued by the Company in March 2019.

# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalyst Rule 704 (8).

### Past (for the last 5 years)

- 1) Clearbridge USA Inc.
- 2) Biomedics Laboratory Pte. Ltd.
- 3) Clearbridge Biomedics Pte. Ltd.
- 4) Cordlife Sciences (India) Pvt. Ltd.
- 5) Cordlife Technologies Pte. Ltd.
- 6) CS Cell Technologies Pte. Ltd.
- 7) Cordlife Stem Cell Technology Limited
- 8) Cordlife Medical Phils., Inc.
- 9) Stemlife Berhad
- 10) PT. Cordlife Persada

### Present

- 1) Clearbridge Dental Holdings Pte. Ltd.
- 2) SAM Laboratory Pte. Ltd.
- 3) Clearbridge BSA Pte. Ltd.
- 4) Cleabridge Biophotonics, Inc.
- 5) Cleabridge Biophotonics FPM, Inc.
- 6) Clearbridge Health (Philippines) Inc.
- 7) Clearbridge Medical (Philippines) Inc. (fka Marzan Health Care Inc.)
- 8) Urban Dental (SG) Pte. Ltd.
- 9) LKDS (Hougang Green) Pte. Ltd.
- 10) LKDS (Yishun) Pte. Ltd.
- 11) LKDS (Simei) Pte. Ltd.
- 12) Dental Focus (Bendemeer) Pte. Ltd.
- 13) Dental Town (AMK) Pte. Ltd.
- 14) Dental Focus (Pioneer) Pte. Ltd.
- 15) DentalFamily (Pioneer) Pte. Ltd.
- 16) Dental Focus (People's Park) Pte. Ltd.

(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?

No

(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?

No

(c) Whether there is any unsatisfied judgment against him?

No

(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?

No

(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?

No

(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?

No

(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?

No

(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?

No

(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?

No

(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-

(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or

Yes

If Yes, Please provide full details

From the period of June 2014 to June 2015 when Mr Liao was the Senior Director of Corporate Development of Cordlife Group Limited. In June 2014, the Competition Commission of Singapore ("CCS") commenced an investigation on Cordlife in relation to its exclusive agreements with baby fair organisers and hospitals that potentially have the effect of limiting competition from other providers of cord blood bank services in Singapore. If these exclusive agreements were found to restrict competition in the cord blood bank industry, Cordlife would have infringed section 47 of the Competition Act (the prohibition against an abuse of a dominant position). Please refer to the link for further information: <https://www.ccs.gov.sg/media-and-consultation/newsroom/media-releases/cordlife-removes-exclusive-arrangements>.

(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or

No

(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or

No

---

(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?

No

---

(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?

Yes

---

If Yes, Please provide full details

Please refer to j(i). Mr Liau was involved in putting the relevant information together and representing the company in settlement discussion with CCS.

---

Any prior experience as a director of an issuer listed on the Exchange?

No

---

If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange

Not Applicable

---

Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)

Not Applicable

---